<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525522</url>
  </required_header>
  <id_info>
    <org_study_id>Lichen_NdYAG</org_study_id>
    <nct_id>NCT03525522</nct_id>
  </id_info>
  <brief_title>Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus</brief_title>
  <official_title>Efficacy of Nd:Yttrium Aluminum Garnet Laser Treatment of Lichen Sclerosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Adolf Lukanovič</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juna d.o.o.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of Nd:Yttrium Aluminum Garnet Laser (Nd:YAG) Treatment of
      Lichen sclerosus in comparison with topical corticosteroid treatment. Half of participants
      will receive laser treatment and the other half corticosteroid treatment and the results will
      be followed for 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lichen sclerosus (LS) is a chronic skin disease of unknown cause and very unpleasant symptoms
      which significantly influences the quality of life of the affected patients. Large majority
      of LS lesions is located in anogenital region where initial white flat papules usually
      develop into large, white patches of thin, itchy skin causing fusion of labia minora,
      narrowing of the introitus and burying of the clitoris. Most common symptoms are itching,
      pain, soreness, burning, dyspareunia and dysuria all strongly interfering with sexual
      function and patient's self image. Existing treatment options with systemic and topical
      medications (oral retinoids, topical steroids) have some drawbacks and recently the use of
      laser was proposed for treatment of LS. This study evaluates the safety and efficacy of
      Nd:Yttrium Aluminum Garnet Laser (Nd:YAG) Treatment of Lichen sclerosus in comparison with
      topical corticosteroid treatment. Half of participants will receive laser treatment and the
      other half corticosteroid treatment and the results will be followed for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients assigned randomly to two groups: laser-treatment group and topical-corticosteroid group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Hystology and photographic assessment performed by independant investigators unaware of the assignement.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual analog scale (VAS) score symptom evaluation from baseline to 3 months</measure>
    <time_frame>Change from baseline to 3 months</time_frame>
    <description>Patients will evaluate symptoms on a 0-10 VAS scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Visual analog scale (VAS) score symptom evaluation from baseline to 1 month</measure>
    <time_frame>Change from baseline to 1 month</time_frame>
    <description>Patients will evaluate symptoms on a 0-10 VAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual analog scale (VAS) score symptom evaluation from baseline to 6 months</measure>
    <time_frame>Change from baseline to 6 months</time_frame>
    <description>Patients will evaluate symptoms on a 0-10 VAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative histological evaluation</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>biopsies taken at baseline and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>1 month</time_frame>
    <description>Patients will indicate their satisfaction with the outcome of treatment on a 0-3 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>3 months</time_frame>
    <description>Patients will indicate their satisfaction with the outcome of treatment on a 0-3 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>6 months</time_frame>
    <description>Patients will indicate their satisfaction with the outcome of treatment on a 0-3 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of improvement from clinical photographs</measure>
    <time_frame>3 months</time_frame>
    <description>by blinded evaluators on a 1-4 scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>tolerability of first laser treatment (pain and discomfort) on a 1-10 VAS scale</measure>
    <time_frame>day 0 (first laser treatment)</time_frame>
    <description>rated by patients in the laser group on a 1-10 VAS scale</description>
  </other_outcome>
  <other_outcome>
    <measure>tolerability of second laser treatment (pain and discomfort) on a 1-10 VAS scale</measure>
    <time_frame>day 14 (second laser treatment)</time_frame>
    <description>rated by patients in the laser group on a 1-10 VAS scale</description>
  </other_outcome>
  <other_outcome>
    <measure>tolerability of third laser treatment (pain and discomfort) on a 1-10 VAS scale</measure>
    <time_frame>1 month (third laser treatment)</time_frame>
    <description>rated by patients in the laser group on a 1-10 VAS scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lichen Sclerosus</condition>
  <condition>Lichen Sclerosus Et Atrophicus</condition>
  <arm_group>
    <arm_group_label>Nd:YAG Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three sessions of Nd:YAG laser (1064 nm) treatment with Dynamis (Fotona, Slovenia)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Corticosteroid Diprosone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical corticosteroid betamethasone (Diprosone, Merck Sharp &amp; Dohme, d.o.o.) for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nd:YAG Laser</intervention_name>
    <description>Three sessions of Nd:YAG treatment every two weeks.</description>
    <arm_group_label>Nd:YAG Laser</arm_group_label>
    <other_name>Nd:YAG</other_name>
    <other_name>neodymium</other_name>
    <other_name>Dynamis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical corticosteroid Diprosone</intervention_name>
    <description>3 months of topical corticosteroids Diprosone</description>
    <arm_group_label>Topical Corticosteroid Diprosone</arm_group_label>
    <other_name>topical corticosteroids betamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed Lichen sclerosus

          -  voluntary signed informed consent

        Exclusion Criteria:

          -  pregnancy

          -  use of photosensitizing medication

          -  pathology other than Lichen

          -  damage of tissues in the treatment area

          -  other inflammation

          -  refusal to sign informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adolf Lukanović, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKC Ljubljana</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Dr Adolf Lukanovič</investigator_full_name>
    <investigator_title>Medical Director of the Division of Gynaecology</investigator_title>
  </responsible_party>
  <keyword>Lichen sclerosus</keyword>
  <keyword>laser</keyword>
  <keyword>Nd:YAG</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Sclerosus et Atrophicus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

